Catalyst Dossier · compiled by CeliA 🧫

Acorda Therapeutics (ACOR)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
CVT-301	Phase 3	Idiopathic Parkinson's Disease
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)	Phase 2	Multiple Sclerosis
dalfampridine-ER 7.5mg	Phase 3	Post-Ischemic Stroke
Tizanidine	Phase 2	Spasticity
Diazepam	Phase 2	Epilepsy
Fampridine-SR	Phase 3	Multiple Sclerosis
Sinemet (carbidopa/levodopa)	Phase 2	Idiopathic Parkinson's Disease
Dalfampridine-ER 5mg	Phase 3	Multiple Sclerosis
CVT-301 Low Dose	Phase 3	Idiopathic Parkinson's Disease
Fampridine-SR b.i.d. (Twice Daily)	Phase 3	Multiple Sclerosis
Dalfampridine	Phase 2	Spinal Cord Injury
Nepicastat	Phase 2	Posttraumatic Stress Disorder
Dalfampridine Pill	Phase 3	Multiple Sclerosis
SYN120	Phase 2	Parkinson's Disease Dementia (PDD)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ACOR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.